Table 1

Clinical profiles of the patients enrolled in this study
No. Sex Diagnosis Age of onset Auto antibodies Reason for adding TAC On starting TAC Complications ascribable to TAC
Anti-Nuclear Antibody Anti-Jo-1 Antibody Disease duration (months) Complications MMT score CK (IU/L) Daily dosage of PSL (mg/day)
1 F PM 17 - - DRP 3 - 50 838 35 -
2 F PM 37 + - DRP 4 - 53 775 30 -
3 F PM 46 - - DRP 5 - 60 666 15 -
4 M PM 55 - - DRP 5 - 60 482 15 -
6 F PM 61 - - DRP 1 - 47 2241 45 -
7 F PM 63 - - DRP 1 - 47 965 30 -
8 F PM 37 - - Recurrence 180 Osteoporosis, multiple rib fracture 40 1809 2.5 -
9 M PM 57 - - Recurrence 32 Glaucoma 60 810 4 -
10 F DM 31 - + DRP 1 - 47 1665 50 -
11 M DM 58 - - DRP 1 - 45 612 60 -
12 F DM 59 - - DRP 1 - 35 3699 30 -
13 F DM 60 - - DRP 1 - 35 3699 50 -
14 F DM 72 - - Recurrence 8 Osteoporosis 35 864 20 -
15 F CADM 24 - - DRP 1 - 60 74 25 -

CADM: clinically amyopathic dermatomyositis, CK: creatine kinase, DM: dermatomyositis, DRP: difficulty in reduction of prednisolone, MMT: manual muscle strength test, PSL: prednisolone, TAC: tacrolimus.

Shimojima et al.

Shimojima et al. BMC Musculoskeletal Disorders 2012 13:228   doi:10.1186/1471-2474-13-228

Open Data